Dr. Reddy’s Laboratories (DRL) saw its shares jump more than 2% after reporting a significant 16.5% increase in revenue for Q2 FY25, reaching a record-high Rs 8,016.1 crore. Despite a 9.5% year-on-year decline in profit after tax (PAT) to Rs 1,341.9 crore, the company’s strong revenue performance exceeded Bloomberg’s expectations by 4.1%.
Sequentially, DRL’s revenue from operations grew by 4 4.5%, while PAT declined by 3.6%. The company also posted a 2.7% rise in EBITDA to Rs 2,390.1 crore, indicating steady operational growth.
As of 9:47 am, Dr. Reddy’s Laboratories shares were trading 2.01% higher at Rs 1,297.80 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
